- In May 2026, Pharvaris N.V. reported a first-quarter net loss of €39.2 million, while completing a US$115.00 million follow-on equity offering of 3,874,664 ordinary shares at US$29.68 each.
- The new capital extends Pharvaris’s funding runway into 2028 as it advances late-stage deucrictibant programs toward regulatory submissions for hereditary angioedema.
- We will examine how this bolstered cash position and progress toward a New Drug Application shapes Pharvaris’s investment narrative.
Find 50 companies with promising cash flow potential yet trading below their fair value.
What Is Pharvaris' Investment Narrative?
To own Pharvaris, you have to believe that deucrictibant can translate its late-stage clinical profile into real-world adoption in hereditary angioedema, despite today’s zero revenue and ongoing losses. The Q1 2026 net loss of €39.2 million underlines how dependent the story remains on clinical and regulatory milestones, particularly the planned New Drug Application for the on-demand deucrictibant capsule and pivotal CHAPTER-3 data in the third quarter of 2026. The fresh US$115.0 million equity raise, extending the cash runway into 2028, meaningfully reshapes the near-term risk-reward: funding risk steps back, while execution and trial-readout risk move firmly to the front of the queue. Recent share price strength suggests the market is already weighting those catalysts heavily, but the core bet still rests on trial outcomes and eventual regulator views.
However, investors should also weigh how ongoing losses and repeated equity raises affect their stake over time. Pharvaris' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other Perspectives
Explore another fair value estimate on Pharvaris - why the stock might be worth just $46.34!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Pharvaris research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Pharvaris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharvaris' overall financial health at a glance.
Seeking Other Investments?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com